Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Francesca, Galardi"'
Autor:
Francesca Galardi, Francesca De Luca, Chiara Biagioni, Ilenia Migliaccio, Giuseppe Curigliano, Alessandro M. Minisini, Martina Bonechi, Erica Moretti, Emanuela Risi, Amelia McCartney, Matteo Benelli, Dario Romagnoli, Silvia Cappadona, Stefano Gabellini, Cristina Guarducci, Valerio Conti, Laura Biganzoli, Angelo Di Leo, Luca Malorni
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC counts in patients en
Externí odkaz:
https://doaj.org/article/2bff5be9c34644208616c14bb489fbff
Autor:
Oriana Nanni, Pierluigi Viale, Bernadette Vertogen, Claudia Lilli, Chiara Zingaretti, Caterina Donati, Carla Masini, Manuela Monti, Patrizia Serra, Roberto Vespignani, Veruska Grossi, Annibale Biggeri, Emanuela Scarpi, Francesca Galardi, Lucia Bertoni, Americo Colamartini, Fabio Falcini, Mattia Altini, Ilaria Massa, Raffaella Gaggeri, Giovanni Martinelli
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-4 (2020)
Abstract Objectives Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. It is believed to block virus infection by increasing endosomal pH required for virus cell fusion and glycosylation o
Externí odkaz:
https://doaj.org/article/0ef0e112022c441aba76d83c73c15281
Autor:
Emanuela Risi, Marta Pestrin, Chiara Biagioni, Dario Romagnoli, Ilenia Migliaccio, Francesca Galardi, Francesca De Luca, Matteo Benelli, Erica Moretti, Giuseppina Sanna, Luca Livraghi, Silvia Cappadona, Roberta Di Marsico, Domenico Amoroso, Angelo Martignetti, Angela S. Ribecco, Elena Rota Caremoli, Luigi Coltelli, Fabio Puglisi, Luca Malorni, Laura Biganzoli
Publikováno v:
Cancer Research. 83:P3-05
Background: In the era of targeted therapies, chemotherapy (CT) is still a valuable treatment option for patients (pts) with HER2 negative metastatic breast cancer (MBC). The identification of predictive and prognostic markers might improve treatment
Autor:
Ilenia Migliaccio, Angela Leo, Francesca Galardi, Cristina Guarducci, Giulio Maria Fusco, Matteo Benelli, Angelo Di Leo, Laura Biganzoli, Luca Malorni
Publikováno v:
Cancers, Vol 13, Iss 11, p 2640 (2021)
CDK4/6 inhibitors (CDK4/6i) and endocrine therapy are the standard treatment for patients with hormone receptor-positive and HER2 negative (HR+/HER2−) metastatic breast cancer. Patients might show intrinsic and acquired resistance, which leads to t
Externí odkaz:
https://doaj.org/article/ee4fa7b6196a405fa6685622ac389fe1
Autor:
Amelia McCartney, Ilenia Migliaccio, Martina Bonechi, Chiara Biagioni, Dario Romagnoli, Francesca De Luca, Francesca Galardi, Emanuela Risi, Irene De Santo, Matteo Benelli, Luca Malorni, Angelo Di Leo
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The recent arrival of CDK4/6 inhibitor agents, with an approximate doubling of progression-free survival (PFS) associated with their use in hormone receptor-positive, HER2-negative advanced breast cancer (BC), has radically changed the approach to ma
Externí odkaz:
https://doaj.org/article/01a7b964ad544666af93b70edebf3015
Autor:
Luca Malorni, Angelo Di Leo, Laura Biganzoli, Dario Romagnoli, Irene De Santo, Emanuela Risi, Francesca Galardi, Ilenia Migliaccio, Matteo Benelli, Mattias Bergqvist, Alessandro Marco Minisini, Erica Moretti, Giuseppe Curigliano, Chiara Biagioni, Francesca De Luca, Martina Bonechi, Amelia McCartney
Baseline characteristics of studied c-TREnd biomarker population - including all patients with at least one sample available for analysis at any timepoint(s), compared to the overall original TREnd cohort. Fisher exact test was used to calculate p-va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdcccb9d6af476d41fcd2d5657c7ac00
https://doi.org/10.1158/1078-0432.22478804
https://doi.org/10.1158/1078-0432.22478804
Autor:
Luca Malorni, Angelo Di Leo, Laura Biganzoli, Dario Romagnoli, Irene De Santo, Emanuela Risi, Francesca Galardi, Ilenia Migliaccio, Matteo Benelli, Mattias Bergqvist, Alessandro Marco Minisini, Erica Moretti, Giuseppe Curigliano, Chiara Biagioni, Francesca De Luca, Martina Bonechi, Amelia McCartney
Purpose:Thymidine kinase 1 (TK1) is downstream to the CDK4/6 pathway, and TK activity (TKa) measured in blood is a dynamic marker of outcome in patients with advanced breast cancer (ABC). This study explores TK1 as a biomarker of palbociclib response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d06d5d972f357c303071297678f37793
https://doi.org/10.1158/1078-0432.c.6530048
https://doi.org/10.1158/1078-0432.c.6530048
Autor:
Dario Romagnoli, Agostina Nardone, Francesca Galardi, Marta Paoli, Francesca De Luca, Chiara Biagioni, Gian Marco Franceschini, Marta Pestrin, Giuseppina Sanna, Erica Moretti, Francesca Demichelis, Ilenia Migliaccio, Laura Biganzoli, Luca Malorni, Matteo Benelli
Publikováno v:
Briefings in Bioinformatics. 24
DNA-methylation alterations are common in cancer and display unique characteristics that make them ideal markers for tumor quantification and classification. Here we present MIMESIS, a computational framework exploiting minimal DNA-methylation signat
Autor:
Francesca Galardi, Francesca De Luca, Dario Romagnoli, Chiara Biagioni, Erica Moretti, Laura Biganzoli, Angelo Di Leo, Ilenia Migliaccio, Luca Malorni, Matteo Benelli
Publikováno v:
Biomolecules, Vol 10, Iss 12, p 1677 (2020)
Liquid biopsy based on cell-free DNA (cfDNA) enables non-invasive dynamic assessment of disease status in patients with cancer, both in the early and advanced settings. The analysis of DNA-methylation (DNAm) from cfDNA samples holds great promise due
Externí odkaz:
https://doaj.org/article/524551d27157468d9820a1ff32acf35d
Autor:
Dario Romagnoli, Francesca Galardi, Francesca De Luca, Chiara Biagioni, Erica Moretti, Laura Biganzoli, Ilenia Migliaccio, Luca Malorni, Matteo Benelli
Publikováno v:
Cancer Research. 82:P3-05
Introduction: Breast cancer (BC) is a heterogeneous disease characterized by different molecular "intrinsic" subtypes (PAM50) with distinct prognostic and therapeutic implications. DNA methylation (DNAm) is one of the most studied epigenetic mechanis